99精品无码,成人在线免费观看网站,人人操天天插,欧美国产乱伦,爽又猛又粗国产免费国产,鸡巴操穴视频,免费无码婬片在线播放,国产免费自拍视频

<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

iLite? ADCC Target CD20 (+) Assay Ready Cells from EAGLE BIOSCIENCES INC.

產(chǎn)品貨號

BM4010

產(chǎn)品價格

現(xiàn)貨詢價，電話：010-67529703

產(chǎn)品規(guī)格

250 ul

產(chǎn)品品牌

EAGLE BIOSCIENCES INC.

產(chǎn)品概述

產(chǎn)品詳情

Edit	&nbsp
Product Name	iLite? ADCC Target CD20 (+) Assay Ready Cells
Description	iLite? ADCC Target CD20 (+) Assay Ready Cells are based on a human B lymphocyte cell line, Raji (ATCC# CCL-86), and have been genetically engineered and optimized to express high and constant levels of the surface antigen CD20. ? Antibody-dependent cell-mediated cytotoxicity (ADCC) is a mechanism whereby pathogenic cells are lysed by lymphocytes, most often Natural Killer (NK) cells. The mechanism involves binding of antibodies to surface antigens on the pathogen. Crosslinking of these antibodies to NK cells through the binding of the Fc-portion to Fc receptors on the NK cells leads to activation of the NK cell and formation of an immune synapse with the pathogenic cell. The NK cell releases cytotoxic granules containing granzymes and perforin into the synapse, leading to apoptosis of the targeted cell. The idea of employing ADCC to destroy dysfunctional cells by treating patients with antibodies has existed since the discovery of the ADCC mechanism. Rituximab, one of the first of such drugs approved, is a chimeric monoclonal antibody targeting CD20, a surface antigen primarily found on B-cells. The drug was approved by the FDA in 1997 for treatment of chemotherapy resistant Non-Hodgkin B-cell lymphomas, and has since also been approved in Europe for different inflammatory indications. In addition, other anti-CD20 monoclonal antibodies have been developed, such as ocrelizumab, a humanized (90-95%) antibody, and ofatumumab, a fully human monoclonal. In addition, efforts are being made to enhance the ADCC activity of the antibodies by engineering the glycan patterns of the constant region, such as in obinutuzumab.
Size	250 ul
Concentration	n/a
Applications	RUO
Other Names	n/a
Gene, Accession, CAS #	n/a
Catalog #	BM4010
Price
Order / More Info	iLite® ADCC Target CD20 (+) Assay Ready Cells from EAGLE BIOSCIENCES INC.
Product Specific References	n/a
產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>